Pharmacia & Upjohn reboxetine
Executive Summary
User fee date for the norepinephrine reuptake inhibitor extended three months to July 28 following submission of additional data to FDA. Phase III data from reboxetine clinical trials was presented during the American Psychiatric Association annual meeting. Data show that the mean reduction in Hamilton Depression Scale total scores for patients in the reboxetine arm was 19.2 compared to a 16.8 HAM-D reduction for fluoxetine (Lilly's Prozac)
You may also be interested in...
P&U Predicts Fourth Quarter Launch For "Approvable" Antidepressant Vestra
Pharmacia & Upjohn and co-promotion partner Janssen expect a fourth quarter launch for the antidepressant Vestra (reboxetine), following FDA "approvable" designation July 29.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011